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Ebola virus (EBOV) causes a deadly hemorrhagic fever in humans and non-human primates. 
There is currently no FDA-approved vaccine or medication to counter this disease. Here, we 
report on the design, synthesis and anti-viral activities of two classes of compounds which show 
high potency against EBOV in both in vitro cell culture assays and in vivo mouse models Ebola 
viral disease. These compounds incorporate the structural features of cationic amphiphilic drugs 
(CAD), i.e they possess both a hydrophobic domain and a hydrophilic domain consisting of an 
ionizable amine functional group. These structural fe tures enable easily diffusion into cells but 
once inside an acidic compartment their amine groups became protonated, ionized and remain 
trapped inside the acidic compartments such as late endosomes and lysosomes. These 
compounds, by virtue of their lysomotrophic functions, blocked EBOV entry. However, unlike 
other drugs containing a CAD moiety including chloroquine and amodiaquine, compounds 
reported in this study display faster kinetics of accumulation in the lysosomes, robust expansion 
of late endosome/lysosomes, relatively more potent suppression of lysosome fusion with other 
vesicular compartments and inhibition of cathepsins activities, all of which play a vital role in 
anti-EBOV activity. Furthermore, the diazachrysene 2 (ZSML08) that showed most potent 
activity against EBOV in in vitro cell culture assay  also showed significant survival benefit with 
100 percent protection in mouse models of Ebola virus disease, at a low dose of 10 mg/kg/day. 
Lastly, toxicity studies in vivo using zebrafish models suggest no developmental defects or 
toxicity associated with these compounds. Overall, these studies describe two new 
pharmacophores that by virtue of being potent lysosomotrophs, display potent anti-EBOV 
















The latest Ebola virus disease (EVD) epidemic hit West Africa from late 2013 to mid-2016, 
resulting in more than 11,000 deaths.[1] The average f tality rate (about 40%) was lower than in 
many of the previous outbreaks (up to 90%). However, th  number of cases exceeded all 
previous outbreaks combined by more than tenfold and the number of deaths by more than 
sevenfold.[2] A more recent outbreak has been report d in West Africa with a total of 78 cases of 
hemorrhagic fever, including 44 deaths so far.[3]  
EBOV is a single-stranded, negative sense RNA virus and is a member of the genus Ebolavirus 
in the family Filoviridae. It is closely related to Marburg virus, which, like Ebola Virus (EBOV), 
causes a hemorrhagic fever in humans and non-human primates.[4] The natural reservoir of 
filoviruses are possibly bats, albeit transmission to humans can also occur via non-human 
primates and possibly other animals as well.[5] 
Currently there is no FDA licensed drug, vaccine or any other therapeutic to treat EVD.[6] At 
least three vaccine candidates have shown promising results and have entered clinical trials to 
various degrees.[7-10]7,8,9,10 The unpredictable nature of occurrence of new outbreaks, followed 
by a prolonged period usually taken to attribute the patients’ symptoms to EVD, often results in 
rapid spread of the contagion. This underlines the need for a readily available therapeutic, with a 
long shelf life and one that could be easily stored. Research conducted by different teams,[11-
14]11,12,13,14 as well as our own,[15-17]15,16,17 has provided a number of active small molecule 
EBOV inhibitors, that could meet the aforementioned criteria (Figure 1). Favipiravir, BCX4430 















More recently, repurposing drug screens identified small molecules belonging to cationic 
amphiphilic drugs (CADs) family, as potent inhibitors of EBOV entry.[18-20]18,19,20 CADs are a 
wide group of chemicals that typically have both a ydrophobic domain containing an aromatic 
ring system and a hydrophilic domain containing an ionizable amine functional group.[21] These 
structural features, enables easily diffusion into cells but once inside an acidic compartment their 
amine groups become protonated, ionized and remain trapped. As a result, CADs are 
lysosomotropic, i.e., accumulate to high concentrations in the acidic compartments such as Late 
Endosomes and Lysosomes (LE/Ly) thereby altering their morphology and functions. Regardless 
of their intended target, many FDA approved drugs with a CAD moiety in their backbone, 
blocked EBOV entry in in vitro assays by altering LE/Ly functions.[13,20]  
EBOV entry is exclusively dependent on EBOV Glycoprotein (GP) trimers that project as long 
spikes on the lipid bilayer envelope. The viral entry begins with the viral attachment to the host 
cell surface followed by virus internalization through macropinocytosis. The virus is then 
trafficked sequentially from the early endosomes to the LE and Ly. In the LE/Ly, the cysteine 
proteases; Cathepsin B and/or Cathepsin L under acidic pH and reducing conditions, cleave GP 
to generate a 17-19 kDa fusogenic version of GP.[22-24]22,23,24 The cleaved GP also unmasks its 
binding site to the LE/Ly resident receptor, the Nimann-Pick C1 (NPC1). GP-NPC1 interaction 
promotes the filovirus/cell membrane fusion, that eventually leads to the release of viral lipid 
membrane enclosed ribonucleoprotein complex (RNP) into the cytoplasm for 
transcription.[25,26] For successful entry,  trafficking of EBOV virions to specific NPC1 
expressing LE/Ly compartments is crucial to promote EBOV fusion with the limiting membrane 
to release the enclosed nucleocapsid into cytoplasm. CADs appear to block these interactions by 














In spite of many CADs being effective in vitro in cell culture assays, only few of them were 
effective in vivo in mouse models of Ebola virus diease. Among the successful ones, 
chloroquine (CQ) and amiodarone at 90 mg/kg, protected mice in one study but failed in 
another.[18,27-29]18,27,28,29 Amodiaquine (AQ) did not protect mice,[29] but its usage in humans 
during 2014 EBOV outbreak, in place of an antimalari  containing lumefantrine at Médecins 
Sans Frontières-led treatment units, was associated wi h an observed decrease in human fatality 
rates.[30] Toremifene (Figure 1) at 60 mg/kg protected mice but the doses used were higher than 
what was normally tested for clinical usage and hence is potentially associated with serious side 
effects.[13] Sertraline offered 70% and Bepridil offered 100% protection of mice at a lower 
dosage of 20 mg/kg/day and 24 mg/kg/day, respectively.[20] Potency differences may correlate 
with interactions with lipid and protein moieties within the LE/Ly compartments that ultimately 
impact EBOV entry. However, the primary intended target of the approved drugs was not to 
function as CADs and their anti-EBOV activity required several 10-100 higher fold usage of the 
drug in in vitro studies when compared to their activity against their original intended target. 
Their application in animal models would require re-testing tolerability at higher doses and are 
compounded by the complications of their effects on their primary intended targets. Therefore, a 
more efficient CAD that disrupts EBOV entry without causing any serious side effects would be 





























EC50 = 0.06-0.14 µM
in vivo (mice): not active











EC50 = 3.4-11.8 µM









EC50 = 0.70 µM





EC50 = 0.97-1.73 µM








EC50 = 67 µM
in vivo (mice): 100%, 30 mg/kg/d  
Figure 1. Selected examples of small molecule EBOV inhibitors. 
 
Here, we report on the development of a novel anti-EBOV pharmacophore with a 1,4-
naphthyridine core (Chart 1). Furthermore, for the first time the synthesis of diazachrysene 
derivatives substituted by two different aminoalkyl side chains has been achieved, diverging 
from 1 (ZS48) and alike.[17,31]  The synthesis, pharmacokinetic analysis, in vitro and in vivo 
antiviral screening efforts, and detailed mechanism of action (MOA) studies suggest that the 
studied compounds are CADs with unique features and represent the most potent inhibitors of 




































aminoalkyl derivatives of 1,4-naphthyridine
aminoalkyl derivatives of 4,10-diazachrysene
with two different substituents  
 
RESULTS AND DISCUSSION 
Synthesis 
Being aware that increased number of aromatic rings may disfavor our drug development efforts 
based on 4,10-diazachrysene core,[32] beside extensive toxicity evaluation thereof, we entered 
the core ring re-grouping to two central aromatic rings aiming at naphthyridine core instead 
(Figure 2). Furthermore, the envisioned naphthyridine derivatives have a structural similarity to 
the FDA approved antimalarial drug CQ, which was found to have moderate anti-EBOV 
activity.[18,27] The planned naphthyridine compounds would preserve the 4-alkylaminopyridine 
constitutional motif, akin to alkylamino substituted 4,10-diazachrysenes, which appears to 






















































chloroquine, CQ5 4 




Figure 2. Planned transformations: a) Desymmetrization 1→2; b) Core reduction 1→3; c) CQ 
surrogates.  
Firstly, two naphthyridine core compounds, 6[34,35] and 7[36-38]36,37,38 were synthesized using 
slightly modified approaches than those already known (see Supporting Information 1). These 
two compounds were then subjected to microwave-assisted nucleophilic substitution reactions 
with appropriate amines. This gave rise to 12 alkylmino substituted compounds (3-5 and 8-16, 

























6: R = H
7: R = Cl
R' = H
5: R'' = -CH(CH3)(CH2)3N(CH2CH3)2, 78%
8: R'' = -(CH2)3N(CH2CH2)O, 91%
9: R'' = -(CH2)3N(CH2CH3)2, 59%
10: R'' = -CH2CH(OH)CH2N(CH2CH3)2, 54%
11: R'' = -(CH2)4NHR''', 38% 
R' = -NHR''
3: R'' = -(CH2)2N(CH2CH2)2O, 71% 
4: R'' = -CH(CH3)(CH2)3N(CH2CH3)2, 51%
12: R'' = -(CH2)3N(CH2CH2)2O, 33%
13: R'' = -(CH2)3N(CH2CH3)2, 41%
14: R'' = -CH2CH(OH)CH2N(CH2CH3)2, 67%
15: R'' = -(CH2)2N(CH2CH3)2, 46%











Our initial diazachrysene structures were substituted with two identical aminoalkyl 
sidechains.[17]  Therefore, for the synthesis of unsymmetrically substituted diazachrysenes, the 
experience in tuning up the conditions for microwave- ssisted nucleophilic aromatic substitution 
on the diazachrysene core[31] helped us optimize the procedure that resulted in monosubstitution 
reaction keeping one chloro substituent intact (Scheme 2). The remaining chlorine in 18 was then 
substituted with different aminoalkyl side-chains. In addition, we synthesized three uniformly 































2: R = -(CH2)4N(CH2CH2)2O, 56%
19: R = -(CH2)3N(CH2CH3)2, 40%
20: R = -CH2CH(OH)CH2N(CH2CH2)2O, 73%
a) NH2(CH2)2N(CH2CH2)2O, NMP, MW, 150 
oC, 20 min; 
b) 1. RNH2, NMP, MW, 180 











21: R = -(CH2)2O(CH2)2N(CH3)2, 89%
22: R = -(CH2)4NH2, 72%






Inhibitory Activity Against EBOV  
The compounds were screened for their antiviral activity in cell based High throughput, high 
Content Imaging (HCI) assay, and their EC50 and/or EC90 and CC50 were assessed by running a 
dose response curve analysis (Table 1).[39,40] Briefly, HeLa or human foreskin fibroblast (HFF) 
cells were pretreated with different doses of the compounds for 2 h prior to incubating with 
EBOV. Forty-eight hours post infection (following multiple cycles of viral infections), cells were 
subjected to immunofluorescence analysis (IFA) followed by HCI assay to evaluate the 
percentage of EBOV-GP expressing cells. Diazachrysene d rivatives were tested as water 




































3 not active - >25 - 
4 0.78 4.73 >10 >13 
5 ~10 - - - 
8 not active - - - 
9 ~10 - - - 
10 not active - - - 
11 2.87 13 >25 >8.7 
12 ~10 - - - 
13 4.82 37.43 >10 >2 
14 not active - - - 
15 14.11 62.6 >25 >1.8 
16 2.24 9.9 >25 >11.2 
19 0.79 4.85 >10 >12.6 
20 0.60 3.50 >10 >16.7 
21 3.53 6.74 7 2.0 
22 ~10 23.5 >10 >1 
23 ~10 20.5 >10 >1 















Table 1: EC50 or EC90, which is the effective concentration to achieve 50% or 90% infection 
inhibition respectively, and CC50 (50% cytotoxicity) was accomplished by running the dose 
response curve analysis in four replicates (n = 4). Selectivity index (SI) =CC50/EC50. HeLa cells 
were used for assays, unless noted otherwise. aHFF cells.  bVero cells.  
 
Several bis-aminoalkyl naphthyridine derivatives (4, 13, and 16) were found active in this assay 
(Table 1) with compound 16 with morpholino substituents connected with four carbons to 
aromatic moiety among the most active anti-infectives with EC50 = 2.24 µM. Other bis-
aminoalkyl derivatives, such as 4 and 13, were also considerably active, with EC50 = 0.78 µM 
and 4.82 µM, respectively. Moreover, the low EC90 = 4.73 µM emphasized the possible high 
potency of 4 as anti-EBOV inhibitor. Interestingly, 11, which possesses 7-chloroquinoline 
moiety as its side-chain (a feature of CQ) also has acceptably good in vitro activity with EC50 = 
2.87 µM, contrary to the mono-aminoalkyl substituted naphthyridines (5, 8, 9 and 10) which 
appeared either completely inactive or possessed borderline activity in our screen.  
Diazachrysene derivatives with dissimilar aminoalkyl substituents, 2, 19 and 20 showed 
improved anti-EBOV activity (Table 1) as compared to their symmetrically substituted analogue 
1 and related compounds[31] with EC50 = 0.26-0.79 µM, and they also retained the low level of 
cytotoxicity. The inhibitor 2, EC50 = 0.26 µM, EC90 = 0.85 µM, appeared as one of the most 
potent EBOV inhibitors known.[16,41,42] The most active new compound 2, as well as our 
preceding derivative 1, were further tested in a primary cell-based assay, in HFF cells. The 
activity proved to be consistent with HeLa based assay results.  
Symmetrically substituted diazachrysene derivatives 21, 22 and 23 showed no improved activity 














Pharmacokinetic analysis and physicochemical properties  
The in vitro ADME profile for compounds 2, 4, and 13 (Table 2) was encouraging. Both 
naphthyridines 4 and 13, as well as the diazachrysene 2, showed good plasma stability (60 or 
>85% remaining after 1 h), adequate solubility at pH 7.4 (>50 g/mL), low to moderate CYP 
inhibition, and high mouse and human microsomal stability. Compound 2, the most potent 
inhibitor, was further shown to be highly permeable in an MDCK permeability assay. 
 
Table 2. ADMET parameters for 2, 4, and 13.[43]  
Parameter tested 2  4  13  
Plasma stability, 1h, 37 °C (%)a 60 >85 >85 
Solubility, pH 7.4 (µg/mL)b >50 >50 >50 
CYP3A4 / BQ inhibition (µM)c >10 >10 >10 
CYP3A4 / DBF inhibition (µM)c >10 >10 >10 
CYP3A4 / BFC inhibition (µM)c >10 >10 >10 
CYP2D6 / AMMC inhibition (µM)c >10 8.0 >10 
CYP2C19 / CEC inhibition (µM)c >10 3.6 >10 














Microsomal t1/2 mouse / human (min)
d 62.1/42.1 42/>60 >60/>60 
 Permeability A→B (10-6 cm/s)e 39.3 - - 
Permeability B→A (10-6 cm/s)e 43.2 - - 
aPlasma stability (percent remaining after 1 hour), determined following incubation for 1 hour 
at 37 °C. bCompound solubility, determined using laser nephelom try to measure light scattering, 
performed in triplicate. cThe IC50 values for CYP inhibition, determined from the netfluorescent 
signal from incubation at 37°C for a set time with an active cytochrome P450 enzyme and a 
fluorescent probe substrate. dClearance in mouse and human models, substrate depletion 
experiments were performed by incubating test compound with liver microsomes for 1 hour at 37 
°C; in this test t1/2>30 min is considered good. 
eApparent permeability (PAPP) of compounds 
determined with Madin Darby Canine Kidney (MDCK) Cell line; A→B apical to basolateral 
membrane movement; B→A basolateral to apical membrane movement; three biological 
replicates.  
 
In order to assess the efficacy of diazachrysene transport, the interactions of 2 and 1 with HSA 
and AGP proteins, respectively, have been evaluated utilizing changes in fluorescence spectra of 
proteins upon addition of increasing amounts of each compound (see Supporting Information 1). 
The binding constants (KSV) were (6.12±0.20) × 10
4 M-1 for AGP and (8.85±0.30) × 104 M-1 for 
HSA (for 2); and (8.12±0.07) × 104 M-1 for AGP and (1.13±0.04) × 105 M-1 for HSA (for 
1).[44,45] 
Furthermore, during in vivo tolerability evaluation f 2 in healthy mice (vide infra) mouse serum 
was collected and analyzed for total compound levels, and possible metabolites thereof.[46] 
Total concentration of compound 2 was detected in serum (0.35-1.20 µM) 24 h after last 20 
mg/kg dose was administered, as presented in Figure 3. The detected concentration is 
conveniently in the range of the compound’s EC90 value (0.85 µM), exceeding the EC50 value 














cell assays and the LC50 value of 18.9 µM (zebrafish assay, see Supporting Information 1). 
Moreover, this serum concentration relative to EC50 is similar to that for our diazachrysene 
compound 1 (0.46-1.03 µM; Supporting Information 1) which was efficacious in a mouse model 
of EBOV infection.   
   
 
Figure 3. Chromatograms of quantification of free 2 (ZSML08) levels in mouse serum. Samples 
from two mice treated with 20 mg/kg/day of 2 (ZSML08) were taken 24 hours after the last dose 
and prepared as described in Supporting Information 1. Chromatograms were obtained using 
UHPLC/MS. No products of reduction (M+2), oxygenation (M+16), dehydrogenation (M-2), 
bis-oxygenation (M+32) or of any combination thereof were detected.  
 
The ability of a compound to be protonated inside of the endosome is critical for the CAD 














4, 13) were experimentally determined by potentiometric titration in four replicates as presented 
in Table 3 and Figure 4 (conjugated acids, Supporting Information 1), as well as for CQ and 1, 
for comparison. This allowed the calculation of thenet charge for the compounds at 
physiological and lysosomal pH (Table 3). Furthermore, the distribution coefficients at 
pH=7.3±0.1 were calculated using ACD/Labs software.  
 
Table 3. Experimental acidity constants of selected compounds and calculated distribution 
coefficients. 
















117 5.96 5.24 7.35 4.37 0.54 2.72 2.71 
2 6.65 5.60 7.70 4.56 0.87 3.04 2.53 
4 10.81 8.41 5.72 / 1.94 2.84 1.36 
13 10.97 8.50 5.51 / 1.95 2.76 -0.18 
CQ 9.18 / 7.45 / 1.54 1.99 1.53 
apKa values of alkylamino side-chains. bpKa values of one or two aromatic nitrogens at the 
core. cTotal degree of protonation (net charge) at (physiolog cal) pH = 7.35 and pH = 5.0 
(lysosome), respectively, calculated from pKa values (approximating the ionic strength of 






































pKa sidechain 1pKa sidechain 1




4                                                               2  
Figure 4. Sites of protonation from pKa determination experim nt.  
 
The pKa measurement results showed that naphthyridine derivatives 4 and 13 are more basic 
than diazachrysenes 2 and 1, having two times higher net charge at physiological pH. This fully 
corresponds to their computed clogD values which are lower than the values of diazachrysene 
derivatives. The charge at physiological pH deserves a few comments: diazachrysenes, 2  and 1, 
are less than monoprotonated at pH 7.35 and charge distribution sits ca. 79-93 % at core nitrogen  
and the rest stays on morpholine nitrogens (Supporting Information 1).[48,49] Therefore, the 
positive charge delocalization across the aromatic diazachrysene core should ease the plasma 
transport and passage across membranes of 1 and 2 over 4 and 13 (both possessing +2 localized 
charge at side-chain nitrogens) as in vivo results would suggest. On the other hand, the charge at 
pH 5.0 (lysosomal compartments) is very similar for all new compounds, being ~3.0; therefore, 
the higher degree of protonation is expected to prevent the compound from leaving the 















Toxicity profiling  
The most promising EBOV inhibitor 2, and 1 and CQ for comparison, were thoroughly 
investigated for toxicity in vivo (mortality, teratogenicity, cardiotoxicity, hepatotoxicity and 
myelosuppression) using zebrafish embryos (Figure 5). 
 
 
Figure 5. A. The results of toxicity assay on zebrafish embryos at 120 h hours post fertilization 
(hpf) exposed to antiviral drugs 2 (ZSML08), 1 (ZS48) and CQ, expressed as the LC50 (µM). B. 
Morphology of wild type (wt) zebrafish embryos after the treatments with 30 µM of 2 
(ZSML08), 40 µM of 1 (ZS48) and 40 µM of CQ. The embryonic liver is indicated with a red 
curved area. C. In vivo imaging of the liver morphology of Tg(l-fabp:EGFP) zebrafish larvae 
treated with 2 (ZSML08) and 1 (ZS48) confirming the lack of their hepatotoxicity upon applied 














The antivirals 1 and 2 exhibited a dose-dependent mortality and did not induce any appearance 
of teratogenic (developmental) malformations in the surviving embryos (Figure 5; Supporting 
Information 1). As the cardiotoxicity and the liver toxicity are the most common drawbacks of 
the drugs approved for human use, diazachrysenes 1 and2 were checked for the above toxic 
effects every day within 72-120 hours post fertilizat on (hpf). The obtained results showed no 
cardiotoxic effects in any of the surviving embryos, such as the appearance of pericardial edema 
(Figure 5B) and the disturbed heartbeat rate (data not shown). 
To address the possible hepatotoxicity of selected diazachrysenes, we explored their effect on the 
liver development (applying compounds at 6 hpf when the liver has not yet been formed) and 
function (applying compounds at 72 hpf when the livr is fully functional) using the transgenic 
Tg(l-fabp:EGFP) zebrafish embryos with fluorescently labeled liver. The hepatotoxicity was 
evaluated at 120 hpf old embryos, using the liver ar a index (the ratio of liver area and lateral 
body area) that proved to accurately represents the liver damages.[51] As shown in Figure 5C, 
the antivirals 2 and 1 did not change the liver area index nor its fluorescence at any tested dose 
up to 30 µM and 40 µM, respectively, irrespective to the time of addition (Figure 5B, 5C, 
Supporting Information 1), thus clearly demonstrating no liver toxicity even at concentrations 73 
times higher than cell based activity EC50 (for 2) and 103 times higher (for 1). On the contrary, 
CQ significantly reduced both the liver area index (P < 0.05) and fluorescence at ≥ 30 µM if 
administered at 6 hpf (Figure 5B, C), and at ≥ 80 µM when applied at 72 hpf (Supporting 
Information 1).  
Since myelosuppression is also one of the adverse side effects of many clinically used drugs, the 
antivirals 1 and 2 were examined for toxicity in vivo towards neutrophils. To address this 














labeled neutrophils, thus enabling direct visualization of applied compounds on the neutrophil 
genesis and occurrence. Obtained results revealed that 1 and 2 exerted no myelotoxic effect at 
any tested concentration up to 20 µM and 40 µM respectively, as determined by the whole 
embryos fluorescence (Figure 6). CQ appeared to be myelotoxic and markedly reduced the 















Figure 6. The effect of 2 (ZSML08) and 1 (ZS48) on the neutrophil population assessed in 
Tg(mpx:GFP) zebrafish embryos with GFP-labeled neutrophils at 72 hpf. Neutrophil 
fluorescence (A) and occurrence (B) upon the treatmn  with 2 (ZSML08), 1 (ZS48), and CQ. 
 
To address the therapeutic potential of the explored compound, the toxicity was evaluated by 
determination of the lethal concentration (LC50, Supporting Information 1), defined as the 
treatment concentration resulting in 50% mortality of embryos over a period of 120 hpf. The 
obtained results reveal a very good therapeutic potential of both diazachrysenes that showed a 
low overall toxicity with the LC50(2 (ZSML08)) = 18.9 µM and LC50(1 (ZS48)) = 72.1 µM. The 
observed toxicity is ~70-100 times lower than their r spective inhibitory activity against EBOV 
observed in HeLa (HFF) cells, Table 1.   
 
Tolerability studies in mice 
Six healthy mice were subjected to seven daily doses f 2 (20 mg/kg, a dose twice as high as the 
one used in the EBOV challenge test; i.p. administration, c.f. Supporting Information 1). The 
mice were then observed twice daily for behavior and ppearance for a total of 28 days after the 
last administered dose. No overt manifestations of acute toxicity were observed.  
 
Compound 2 Protected Mice from EBOV 
Based on the above potency, cellular toxicity, ADME, tolerability and PK properties, results, the 














evaluated for in vivo efficacy in a mouse model of EBOV infection[52] using three different 
doses of 10, 5 or 1 mg/kg (Figure 7). This mouse model has been often used for evaluating 
different antivirals.[20,27,41,53-55]53,54,55 A third compound, 13, a less active homologue of 4, 
was also chosen for comparison. Compound 2 showed a dose dependent protection with 100% 
protection at a dose of 10 mg/kg and 50% protection at lower doses of 5 mg/kg and 1 mg/kg 
(Figure 7A). Although uniform mice lethality was not observed in the vehicle treated control 
group infected with mouse adapted Ebola virus, a statistically significant (p = 0.0013) increase in 
survival was observed in the 2 (ZSML08) (10 mg/kg) treated group compared to control group. 
Furthermore, minimal weight loss of the surviving mice was observed (Figure 7B). There was 
also 40% survival with 4 at its highest dose of 10 mg/kg (Figure 7C-D). These in vivo protection 
data corroborated with the compound’s anti-viral activity derived from cell based assay (Table 1) 















Figure 7. The compound 2 (ZSML08) conferred most protection in mice from EBOV challeng .  
Mice (n = 10 mice/group) were treated with indicated concentrations of the compounds at 2 h 
prior to challenge with 1000 plaque forming units (PFU) of mouse-adapted EBOV. Treatment 
was continued daily for six days. The percent survival curves and the corresponding percent 
mean body weight change relative to day 0 (just prior to treatment or challenge) with 2 
(ZSML08) (A-B), 13 (ZS102) (C-D) and 4 (ZS103) (E-F) during the 14 days period of study. 
The P values were evaluated using log-rank test to compare survival rate with the control group. 

















Investigation on the mechanism of action of diazachrysenes 
Compounds 1 and 2 Blocked Viral Entry  
 
Figure 8. 1 (ZS48) and 2 (ZSML08) target viral entry. (A) Time of Compound Addition assay 
(TCA) in which cells were untreated (mock) or treated with 2 (ZSML08) (at 2 µM) at 2 h prior 
to infection (-2 h), or concurrent with virus infection (0 h), or at various time points post-
incubation with EBOV (MOI=10 for 24 h), followed by immunofluorescence analysis (IFA) and 
HCI assay to determine the percentage of GP expressing cells. The infections at each time point 
were normalized with mock treated cells to determine the infection inhibition. (B) GFP 
expression by HeLa cells, which were pre-treated at 2 h with the indicated compounds followed 
by infection with rVSV-EBOV-GP-GFP or VSV-GFP viruses for 8 h and 6 h respectively. Cells 
were visualized by staining with Cell MaskDeep Red. (C-D) Same as in B but cells were either 














with rVSV-EBOV-GP-GFP (C) or VSV-GFP (D). Relative infection inhibition for each 
compound treatment was determined by normalizing percentage of GFP expressing cells with 
mock treated cells and subtracting the result with 1. Data is represented as mean ±SD of three 
replicates and is representative of three independent experiments. P values were evaluated by 
multiple t tests. N.S is not significant and ***, P<0.0001 
 
CADs are known to target EBOV entry by modifying the internal milieu of LE/Ly, such that 
viral membrane is unable to fuse with host lysosomal li iting membrane.[19,56] Thus, we first 
examined if 1 (ZS48) and 2 (ZSML08) targeted viral entry by Time of Compound Addition 
(TCA) assay. As shown in Figure 8A, compound treatment prior to infection (-2 h) or at the time 
of infection (0 h) was necessary for its antiviral activity. Treating cells with the compound at 2 h 
after incubating with virus, by when the virus alredy entered cells, had no effect on virus 
infection.[57]  
We next checked if defects in viral entry were indee  specifically related to changes in the 
LE/Ly without influencing early endosomes or other ea ly entry events. To address this question, 
we used recombinant vesicular stomatitis virus (rVSV) that expressed green florescent protein 
(GFP) and either expressed its own GP (VSV-GP) or pseudotyped to express EBOV-GP (VSV-
EBOV-GP) in the place of VSV-GP.[58] EBOV-GP traffick ng to functional LE/Ly 
compartments is critical for its fusion competency, whereas VSV-GP trafficking to the early 
endosomal compartments is sufficient to make it fusion-competent.[59] Thus, if the compounds 
were modulating LE/Ly then their antiviral effects would be more pronounced in VSV infection 














concentration, 1 and 2 inhibited rVSV-EBOV-GP but had no effect on rVSV-GFP infection.  At 
higher concentrations compounds inhibited VSV infection irrespective of the entry mediated by 
VSV-GP or EBOV-GP but were much more sensitive to entry by latter. Two controls, AQ and 
CQ, were also shown to inhibit EBOV entry albeit to a lesser extent.[18,28,60] At higher 
concentrations (50 µM) at which compounds were all cytopathic (Figure 8C-D), all compounds 
inhibited VSV infection. Collectively, these data confirmed that 1 and 2 targeted viral entry 
mostly by modulating LE/Ly functions and were significantly more potent when compared to the 
other structurally related CADs such as CQ and AQ.  
Antivirals 1 and 2 are Lysosomotropic and Modify Acidic Compartments  
Figure 9. Compounds 1 (ZS48)/ 2 (ZSML08) are lysosomotropic. HeLa cells were untreated 
(mock) or treated with Bafilomycin A1 (BafA1) at 0.01 µM, 1 (ZS48) at 2 µM, 2 (ZSML08) at 
2 µM, AQ at 10 µM and CQ at 10 µM for an hour followed by treatment with Lysosensor DND 
189 for 10 min. (A) Cells were washed and then imaged at an excitation/emission of 443/505 nm 
and 405/450 nm for detecting Lysosensor dye and the test d compounds, respectively. (B) The 
intensity/area of the fluorescence emitted by the Lysosensor dye from the collected images as in 
A was further evaluated using image analysis software (Columbus). Each data point is mean ± 














representative of three independent experiments. P value was evaluated by One Way Anova 
analysis. ****, P < 0.0001. 
CADs freely diffuse into cells but once inside an acidic compartment they become protonated 
and remain trapped. The ensuing physiological and morphological changes in the LE/Ly can 
make the virus fusion incompetent. The acidic pH of LE/Ly is also necessary for converting 
EBOV-GP to the cleaved fusogenic form that is essential for viral entry.[61] Thus, we examined 
1 (ZS48) and 2 (ZSML08) effects on the morphology and pH changes of LE/Ly by live cell 
microscopy, using commercially available fluorescent r porter, LysoSensor DND 189, which 
localizes to acidic compartments, and exhibits pH dependent increase in fluorescence intensity 
upon acidification. HeLa cells were pre-treated with the compounds for 1 h prior to imaging cells 
with LysoSensor. Compounds 1 and 2 were also fluorescent that allowed their visualization at an 
excitation (Ex. 405) and emission (Em. 450). There was no fluorescence detected by the 
compound alone under the Ex/Em conditions used for visualizing LysoSensor (data not shown). 
As shown in Figure 9A, antivirals 1 and 2 strongly co-localized with LysoSensor suggesting that
these compounds freely diffused into cells, but once i side the acid compartments, they became 
heavily protonated (~ZSH3
3+, Table 3, Figure 4) and trapped. Furthermore, 1 and 2 induced the 
clustering of LE/Ly at a high density, unlike in mock treated cells, in which they were fewer and 
showed dispersed distribution throughout the cytoplasm (Figure 9, A-B). Surprisingly, there was 
also sharp increase in florescence intensity of the acid compartments, thus ruling out the 
possibility of neutralizing or alkalizing of LE/Ly due to compound protonation. LysoSensor 189 
sharply drops its florescence intensity by both, decreasing pH from 4 to 0.5 or by increasing pH 
from 4 to 9.[62] The plausible explanation for the increase in intensity appears to be due to an 














controls, CQ and AQ showed a minor increase in fluorescence intensity when compared to mock 
treated cells (Figure 10B) but no other changes were noted. As expected, control Bafilomycin A1 
(BafA1) treatment, an inhibitor of vacuolar H+ ATPase that regulates low acidic pH in the 
lysosomal lumen, reduced the fluorescence intensity.[63]  
We next examined if 1 (ZS48) and 2 (ZSML08) expanded the acidic compartments using 
lysosomotropic weak base Acridine Orange (AO). AO binds to DNA and RNA as a monomer 
and emits fluorescence in green channel. However, uptake of AO and its retention in protonated 
(AOH+) form in the acid compartments, increases its local concentration several fold causing 
AOH+ oligomerization and shifting its florescence spectra from green to red. Furthermore, 
increase in the intensity of red fluorescence is propo tional to the increase in concentration of 
AOH+ in LE/Ly.[64] No fluorescence was detected by the compound alone under the Ex/Em 















Figure 10. Compounds 1 (ZS48) and 2 (ZSML08) induce expansion of acidic compartments. 
HeLa cells were pre-treated for 2 h with the indicated compounds followed by incubation with 
Acridine Orange (AO) for 30 min. Cells were washed prior to imaging at the indicated 
wavelengths. (A) The localization of AO and the 1 (ZS48)/ 2 (ZSML08) compounds. In (B) 
images were enlarged to demonstrate co-localization between AO and compounds 1 (ZS48)/ 2 
(ZSML08). In C and D, the total intensity and the average area of florescence emitted by AO 
were evaluated by HCI assay. Each data point is mean ± SD of a replicate of eight wells of a 96 
well plate with approximately 3000 cells per well and is representative of three independent 
experiments. P value was evaluated by One Way Anova analysis. ****, P < 0.0001. *, P < 0.05. 
 
 As shown in Figure 10, treatment with 1 (ZS48) and 2 (ZSML08) had a profound effect on both 
the intensity and distribution of AO when compared to mock treated cells. First, there was a 
robust increase in the red florescence of AO suggesting an expansion of the acidic compartments 
(Figure 10A). Second, compounds strongly co-localized with AO in the acidic compartments 
(Figure 10B) which validated our previous observations of the lysosomotropism of 1 and 2. 
Third, a majority of AO localized to the vesicular compartments that showed dense clustering at 
the perinuclear region while there was very little gr en signal (480 nm emission) in the 
cytoplasm from monomeric AO binding to DNA/RNA. It appears that the expanding LE/Ly 
compartments retained their acidity which culminated in the uptake and retention of a majority of 
AOH+. A small increase in the concentration of lysosomes at the juxtanuclear regions was also 
evident in CQ and AQ treated cells. As expected, the control BafA1 decreased AO red signal in 














LE/Ly without increasing vacuolar pH. We next examined how the inhibitors influence lysosome 
functions that directly impact EBOV entry. 
Antivirals 1  and 2 Inhibited Cathepsin B Activity 
 
Figure 11. Compounds 1 (ZS48)/2 (ZSML08) inhibited Cathepsin B activity. HeLa cells were 
treated with the indicated compounds for 12 h followed by treatment with Magic Red reagent or 
with AO for 10 min and 30 min, respectively. (A) Cells were washed and then imaged at an 
Ex/Em of 590/630 or 520/560 to detect florescence emitt d by the Magic Red or AO, 
respectively. Increase in florescence by Magic Red is indicative of cathepsin B activity. (B) The 
total intensity and the average area of florescence emitted by Magic Red from the images 
collected were evaluated by HCA. Each data point is mean ± SD of a replicate of eight wells of a 
96 well plate with approximately 3000 cells per well and is representative of three independent 
experiments. P value was evaluated by One Way Anova analysis. ***, P < 0.001. **, P < 0.01. 
 
EBOV-GP cleavage by Cat-B and L, which reside in the LE/Ly, are critical for generating fusion 
competent virus. AQ and CQ inhibition of EBOV entry was previously attributed to their ability 
to block cathepsin’s activity.[65] We examined if the same applies to 1 (ZS48) and 2 














compartments of the cells and emits red fluorescence upon cleavage by specific cathepsin. HeLa 
cells were treated with 1 and 2 for 12 h and then incubated with the peptide reporter for 1 h 
following which cells were washed and imaged. 
As shown in Figure 11 (A-B), in cells treated with 1 and 2 there was a marked decrease in 
cathepsin B activity when compared to mock treated controls. We also observed a significant 
enhancement in the reporter activity in AQ and CQ treated cells contradicting a previous 
report.[65] BafA1 treatment, as expected, showed a significant decrease in cathepsin B reporter 
activity. Similar observations were made at lower duration of treatment (6 h) and with Cat-L 
reporter (data not shown), thus leading to our conclusion that 1 and 2 disrupted cathepsins 
activity. 
Antivirals 1 and 2 Blocked Lysosome Fusion with Autophagosome 
Some CADs including CQ and AQ block proper maturation of the lysosomes by disrupting 
lysosome’s ability to fuse with the cargo containing vesicles including NPC1 expressing LE or 
autophagosomes.[66,67] These defects could potentially prevent the EBOV trafficking to the 
NPC1 expressing LE for viral entry. Thus, we examined the autophagosome fusion with 
lysosome using LC3 marker. LC3-I which is cytosolic, is converted into the membrane-bound 
form LC3-II as autophagy progresses, and specifically localizes on the autophagosome 
membrane. The autophagosome subsequently fuses with the lysosome to form the autolysosome. 















Figure 12. Compounds 1 (ZS48) and 2 (ZSML08) blocked autophagy. (A) HeLa cells stably 
expressing GFP-LC3 were treated with the indicated compounds for 4 hours followed by live 
cell imaging to detect GFP clustering. (B) Confocal images at higher magnification as in (A) to 
visualize the spatial distribution of 1 (ZS48)/2 (ZSML08) loaded vesicles and the GFP-LC3-II 
clusters. Note that GFP clusters and 1 (ZS48)/2 (ZSML08) loaded vesicles either did not co-
localize or in some instances were adjacent to eachother with partial overlap at the peripheral 
edges. The white box in the images is enlarged in the inset.  (C) HeLa cells as in (A) were treated 
with indicated concentrations of the compounds for 4 h, followed by image captures. The images 
were analyzed to determine the total number of GFP clusters/per cell. Each data point is mean ± 
SD derived from 8 well replicate of a 96 well plate with approximately 500 cells per well and is 
representative of three independent experiments. (D) Western blots of HeLa cellular lysates that 
















We thus examined microscopically, LC3-II clusters in compound treated cells using a HeLa cell 
line that stably expressed GFP-LC3. As shown in Figure 12 (A-B), all four CADs, 1 (ZS48), 2 
(ZSML08), CQ and AQ showed an increase in GFP-LC3-II clustering compared to mock 
treated cells although the number of GFP clusters p cell were significantly higher in 1 and 2 
treated cells (Figure 12A). Furthermore, most of the GFP-LC3-II clusters did not co-localize 
with 1 / 2 loaded vesicles (Figure 12B), although in some insta ces they overlapped partially at 
the periphery, implying arrested fusion between the lysosome and autophagosome. These 
observations were further confirmed by Western blotanalysis that showed an increase in the 
membrane bound LC3-II expression levels in a dose dependent manner (Figure 12D), with the 
increase in LC3-II clusters being more sensitive to 1 / 2 when compared to CQ and AQ 
treatments. Lastly, a clear difference was noted in the mechanism of autophagy inhibition 
between 1 / 2 and CQ/AQ when the levels of cleaved GFP were compared (Figure 12D, look at 
cleaved GFP levels). The luminal facing GFP-LC3-II in the autolysosome undergoes degradation 
in two steps. First GFP is cleaved followed by its degradation. In agreement with previous 
studies at non-saturating concentrations of CQ (< 50 µM), lysosome functions were not 
completely inhibited thereby allowing accumulation of cleaved GFP levels (Figure 12D). 
However, 1 and 2 were much more sensitive and efficiently blocked GFP-LC3-II degradation 
mostly by blocking autolysosome formation. Collectively, these data imply fusion defects of the 
LE/Ly compartments with the autophagosomes and that antivirals 1 and 2 were many times more 
















Antivirals 1 and 2 Induced Expansion of Vesicular Compartments 
 
Figure 13. Electron microscopy images of 2 (ZSML08) treated HeLa cells. Cells were mock 
treated (A) or pre-treated for 2 h with 2 (ZSML08) prior to mock incubation (B-C) or incubation 
with rVSV-EBOV-GFP for 2 h (F) or 6 h (D, E, G-H) followed by processing samples to acquire 
images by transmission electron microscopy. Inset in B and D were enlarged to images in C and 
E respectively. Black arrows in C point to lamellar and large granules containing vesicles, in F 
point to the rod shaped VSV-EBOV like particles, in G point to multivesicles containing 
compartments, and in H mark the double membraned autophagosomes. 
Lastly, we used electron microscopy to visualize how 2 (ZSML08) modified EBOV trafficking 
and vesicle morphology in HeLa cells. Until this point we did not observe any differential 
activity between compound 1 (ZS48) or 2 (ZSML08) in modifying Lysosome functions and 
therefore we chose compound 2 which was most potent against EBOV and the main subject of 
this study for electron microscopy studies. To thisend, HeLa cells were either mock treated or 
treated with compound 2 for 2 h and then were either left uninfected or infected with VSV-














infection showed a marked expansion in the number and volume of vesicular compartments 
when compared to mock treated cells (Figure 13 A-D). These vesicles accumulated lamellar 
structures, lipids, smaller vesicles and aggregates, implying defects in lysosome hydrolytic 
activities. Furthermore, at early stages of infection (at 2 h), accumulation of bullet shaped VSV-
EBOV-GFP viral like particles in vesicular compartments were visible in 2 infected cells 
suggesting virus internalization (Figure 13F). In addition, several double membraned vesicles 
presumably autophagosomes were also observed (Figure 13H). Lastly, vesicle expansion was 
concentrated to one side of the nucleus further confirmi g our previous observations. 
Collectively, these data confirmed that diazachrysene 2 enhanced vesicle expansion, and 
modified lysosome functions.  
 
Discussion 
Here we present the preparation and antiviral activity examination of the new class of 
heterocyclics, 1,8-dialkylamino naphthyridines. Their structure was based on core reduction 
approach to remodel the diazachrysene core of our succe sful leads, e.g., 1 (ZS48).[31] In 
addition, in fine-tuning of 1 we succeeded to develop the unsymmetrically substit ted class of 
diazachrysenes. All 18 synthesized compounds were scre ned in a HeLa/HFF cell-based assay 
for their anti-EBOV activity. New naphthyridine inhibitors 4, 13 and 16 were found active in 
low-micromolar range, however, our new, unsymmetrically substituted, diazachrysenes 2, 19 and 
20, proved to be the most active compounds in vitro with good CC50/EC50 selectivity index 
(Table 1). The ADMET studies of three most promising derivatives (2, 4 and 13) exposed their 














low clearance give support to our approach to new and stable CADs. Further, the most active 
diazachrysene derivative 2, and its congener 1, were examined in zebrafish toxicity model 
appearing not to induce any teratogenic malformations n survived embryos, along with no signs 
of cardio- and hepatotoxicity, and expressed no myelotoxic effect at any tested concentration.  
Naphthyridines 4, 13, and diazachrysene 2 were submitted to the EBOV challenge test in groups 
of ten mice per each compound using standard dosage regimen (once daily for 7 days). 
Derivative 2 manifested a dose-dependent increase in mice survival w th the highest dose (10 
mg/kg) resulting in 100% survival. Perhaps most importantly, during the entire duration of the in 
vivo studies, the respective mice groups retained th ir weight, which otherwise decreases in mice 
with EVD. Very few known small molecule EBOV inhibitors achieved full protection in mice, 
which points to successful fine-tuning of the hit structure 1.[17] We speculate that the inferior 
activity of naphthyridine derivatives (survival: 40% and 20%) for 4 and 13 as compared to 
diazachrysene 2 could be correlated to their basic physicochemical properties, such as a higher 
positive net charge and lower distribution coefficient at physiological pH (vide supra). In 
addition, low concentration of diazachrysenes in serum, and determined KSV, appear to ensure 
the compound’s efficacy while maintaining safe (nontoxic) drug concentration (total 2: 0.35-1.20 
µM; vs. LC50(2) = 18.9 µM and total 1: 0.46-1.03 µM vs. LC50(1) = 72.1 µM). The main 
transporter plasma proteins are HSA and AGP, which very often scavenge the intended drug 
from reaching the target, and our HSA and AGP measur ments of diazachrysene 2 revealed the 
optimal drug binding and drug release (KSV within 10
4 - 106 M-1).[68-70]68,69,70  
As noted before, several of the FDA approved drugs with anti-EBOV activity belonged to the 
CAD group with EC50 values mostly in the range of 10 µM.[13,18-20,71-73]13,18,19,20,71,72,73 The 














much more potent with EC50 values in the range of 0.2 – 0.7 µM. This could be due to their fast 
kinetics of uptake and retention into the lysosomes and their ability to alter specific interactions 
within the lysosomal compartment that is essential for EBOV entry. As noted above, the pKa 
profile of diazachrysenes allows for a smaller and delocalized charge than many CADs at 
physiological pH, enabling them to pass across membranes more easily. This assumption is 
supported by MDCK-based assays that showed good permeability of 2 at physiological pH.  
Typically, lysosomotropic compounds including CQ and AQ, were thought to disrupt the 
lysosome functions by raising its intra-luminal pH.[74] Lysosomes digest a variety of substrates 
derived from both cellular and extracellular origins via phagocytosis, endocytosis and autophagy 
degradation pathways. This is accomplished by the enclosed hydrolases, including proteases, 
nucleases, lipases, sulfatases or phosphatases, whoe pH optima are usually low (pH 4.5–5). An 
increase in lysosomal pH, can block the hydrolytic activities leading to an accumulation of 
undigested substrates including lipids, protein aggre ates and organelles etc. in the lysosomes. 
However, our data shows that compounds 1 and 2 including CQ and AQ, retained lysosome 
acidity, based on LysoSensor and Acridine Orange staining.  Our data aligns with a more recent 
study which demonstrated that lysosomotropic compounds including CQ, although initially 
(within 30 min) increased lysosomal pH, those changes were transient and were quickly reversed 
(within 2-4 hours).[75] Few other studies too demonstrated that longer incubations of the 
lysosomotropic compounds in many different cell types did retain the acidic pH of the 
lysosome.[76] Thus, our data provides credence to the new observations that disruption in 
lysosomal functions by lysosomotropic compounds maynot be driven by increasing pH.  
The most striking observation was the rapid expansion of lysosomes by compounds 1 and 2 














CQ or few other lysosomotropic compounds, but only upon longer duration of treatment (>24 h) 
and that too at much higher doses (50-100 µM). Recently, Lu et al[75] demonstrated that 
lysosomal expansion by lysosomotropic compounds is regulated by the activation of coordinated 
lysosomal enhancement and regulation (CLEAR) network that controlled expression of multiple 
genes involved in lysosomal biogenesis and lysosome related functions.[75] Compound 
accumulation inside lysosomes was shown to trigger “lysosomal stress program” that lead to the 
translocation of transcription factor including TFEB and TFE3 into the nucleus, to activate genes 
regulating lysosomal functions via binding to the CLEAR elements in their promoters. 
Lysosomal stress also induced a reduction in mTORC1 activity and calcium signaling which 
activated the CLEAR network. These changes were describ d as lysosomal adaptations to 
counter the lysosomal stress. Future studies are required to address if the same holds true with 
compounds 1 and 2 and if these compounds can indeed disrupt calcium s gnaling and mTORC 
activities to induce the CLEAR pathway.  
Despite rapid expansion of lysosomes by 1 and 2, these changes did not necessarily activate 
lysosome functions. Instead and similar to other lysomotropic compounds, severe defects in 
hydrolytic activities of lysosomes were observed.[75] Our EM images, showed an accumulation 
of undigested material inside lysosomes including lar e aggregates of macromolecules, 
membranes, vesicles and lipids. However, unlike othr lysomotropic compounds, cathepsins 
were also inactivated from early on by compounds 1 and 2 treatment, which could be due to 
leakage of cathepsins by alterations in lysosome membrane permeability. While early studies 
suggested that CQ and AQ inhibited cathepsins by increasing lysosomal pH, our data, and 
studies by Lu et al[75], show that compensatory lysosomal adaptions in response to lysosomal 














compartments accompanied by inhibition of hydrolytic activities including inactivation of 
cathepsins might make these compounds more effective antivirals compared to other 
lysomotropic compounds. 
Antivirals 1 and 2 blocked EBOV entry based on time of compound addition and pseudotyped 
viral entry assays. Furthermore, our electron micros opy studies support previous reports which 
show that CADs did not block viral endocytosis but locked late stages of entry by preventing 
viral-host membrane fusion. In the case of compounds 1 and 2, the late entry defects could due to 
defective proteolytic events (loss of cathepsin’s activity) that result in fusion defective GP and or 
also due to impaired trafficking of the virions to NPC1 expressing LE/Ly compartments. The 
fusion between NPC1+ late endosomes and lysosomes plays an essential role in producing fusion 
competent EBOV-GP. Several cellular host factors such as Rabs, SNARE, homotypic fusion and 
protein sorting (HOPS)-tethering complex and Ca2+ ion that regulate the fusion between LE and 
lysosomes were shown to be essential regulators of EBOV entry.[25,77] The same factors also 
regulated fusion between lysosomes and autophagosomes.[78] Our studies show that compounds 
disrupted the ability of LE/Ly to undergo normal vesicle fusion by monitoring fusion between 
lysosomes and autophagosomes. Further studies are required to determine the direct fusion 
defects between the LE and Ly. Overall, our data suggest that 1 and 2 efficiently prevented 
trafficking of EBOV-GP to appropriate NPC1+ LE compartments or that these compartments 
were defective in the generation of a fusion competent EBOV-GP.  
CADs are known to induce phospholipidosis, upon chronic treatment and at therapeutically 
relevant concentrations.[73,79] This phenotype is similar to the Niemann Pick type-C (NPC) 
disease, a lipid storage disease caused by lipid accumulation inside the vesicles. However, these 














CADs in clinical use are well tolerated; phospholipidosis induced by CADs is not associated 
with the clinical outcome, the lipid accumulation is reversible upon the removal of CADs and the 
duration of treatment with CADs in Ebola viral disea  is also short spanning few weeks to 
months. Overall the presented studies clearly emphasize the effectiveness of our antivirals of 
diazachrysene class, 1 and 2, as prominent candidates for further structure-based development in 
quest for anti-Ebola drug. 
CONCLUSION 
Here, we report on the synthesis of the novel anti-EBOV pharmacophore with potential for 
further development – aminoalkyl substituted 1,4-naphthyridine. In addition, we optimized our 
diazachrysene-based compounds, as to obtain an EBOV inhibitor of high potency, compound 2 
(EC50/EC90 (HeLa) = 0.26 µM/0.85 µM). This compound also protects mice infected with EBOV 
with minimal weight fluctuation during the 14-day experiment. Zebrafish extensive tests 
revealed no teratogenicity, cardiotoxicity, hepatotoxicity and no myelotoxic effects of our 
diazachrysenes 1 and 2 which were well tolerated in healthy mice. We suggest that the observed 
tolerability and efficacy in mice could be correlatd to low positive net charge of 1 and 2 at pH 
7.35 that should ease the plasma transport (measured KSV within 10
4 - 106 M-1), good observed 
apparent permeability, and low total drug concentration in serum (ca. 1 µM). It was also found 
that our compounds specifically inhibit viral entry b  interfering with cellular LE/Ly pathways 
thereby obstructing the prerequisite conditions for EBOV glycoprotein mediated viral ingress. 
Finally, we report on other beneficiary effects of our compounds, such as cathepsin inhibitory 


















Melting points were determined on a Boetius PMHK apparatus and were not corrected. IR 
spectra were taken on a Thermo-Scientific Nicolet 6700 FT-IR diamond crystal. 1H and 13C 
NMR spectra were recorded on a Varian Gemini-200 spectrometer (at 200 and 50 MHz, 
respectively), and a Bruker Ultrashield Advance III spectrometer (at 500 and 125 MHz, 
respectively) in the indicated solvent (vide infra) using TMS as the internal standard. Chemical 
shifts are expressed in ppm (δ) values and coupling constants (J) in Hz. ESI–MS (HRMS) 
spectra of the synthesized compounds were acquired on a Agilent Technologies 1200 Series 
instrument equipped with Zorbax Eclipse Plus C18 (100 × 2.1 mm i.d. 1.8 µm) column and DAD 
detector (190-450 nm) in combination with a 6210 Time-of-Flight LC/MS instrument in positive 
ion mode. The samples were dissolved in pure H2O (HPLC grade). The selected values were as 
follows: capillary voltage 4 kV; gas temperature 350 °C; drying gas 12 L min-1; nebulizer 
pressure 45 psig; fragmentator voltage: 70 V. Lobar LichroPrep Si 60 (40-63 µm) or LichroPrep 
RP-18 columns coupled to a Waters RI 401 detector were used for preparative column 
chromatography. Mass spectral analyses were done usi g electrospray ionization in positive ion 
mode on a Surveyor separations module coupled to a ThermoFinnigan TSQ AM triple 
















HPLC purity determination 
Compounds 2-5, 8-15 and 19-23 were analyzed for purity (HPLC) using a Waters 1525 HPLC 
dual pump system equipped with an Alltech Select degasser system and dual λ 2487 UV-VIS 
detector and using an Agilent 1200 HPLC system equipped with a Quat pump (G1311B), an 
injector (G1329B) 1260 ALS, TCC 1260 (G1316A) and a etector 1260 DAD VL+ (G1315C). 
HPLC analysis was performed using two of several different methods:  
Method A: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 
150 mm, 1.8 µ, S.N. USWKY01594). Compounds were dissolved in water. The final 
concentrations were ~ 1 mg/mL, and the injection volume was 3.0 µL for compounds 2 and 20 
and 4.0 µL for compounds 19 and 21-23. The eluent was made from the following solvents: 
0.2% formic acid in water (A) and methanol (B). Wavelength = 254 nm. 
Method B: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 
150 mm, 1.8 µ, S.N. USWKY01594). Compounds were dissolved in water. The final 
concentrations were ~ 1 mg/mL, and the injection volume was 1.0 µL for compounds 2 and 20 
and 4.0 µL for compounds 19 and 21-23. The eluent was made from the following solvents: 
0.2% formic acid in water (A) and acetonitrile (B). Wavelength = 254 nm. 
Method C: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 
150 mm, 1.8 µ, S.N. USWKY01594). Compounds were dissolved in methanol. The final 
concentrations were ~ 1 mg/mL, and the injection volume was 0.5 µL for compounds 9, 10 and 
14, 1 µL for compounds 4 and 5, 2 µL for compounds 8, 12 and 13 and 3 µL for compounds 3,














Wavelength = 239 nm (4, 12, 14), 253 nm (5, 8-10), 328 nm (13), 338 nm (11), 341 nm (3, 15 
and 16). 
Method D: Octadecylsilica was used as the stationary phase (Zorbax Eclipse Plus C18 4.6 x 
150 mm, 1.8 µ, S.N. USWKY01594). Compounds were dissolved in methanol. The final 
concentrations were ~ 1 mg/mL, and the injection volume was 0.5 µL for compounds 4, 5, 9, 10, 
13 and 14, and 1 µL for compounds 3, 8, 11, 12, 15 and 16. The eluent was made from the 
following solvents: water (A) and acetonitrile (B). Wavelength = 239 nm (4, 5, 8-10 and 12-14), 
338 nm (11), 341 nm (3, 15 and 16). 
All compounds were > 95% pure.  
 
Synthesis 
Refer to Supporting Information for individual procedures, yields and characterization. Only 
General procedures follow: 
General procedure for the preparation of 1,7-bis(alkylamino)-4,10-diazachrysenes  
Compound 17[31] and an excess of the appropriate amine were dissolved in NMP in a MW 
cuvette under argon. The reaction mixture was subjected to MW irradiation using Biotage 
Initiator 2.5 apparatus for 6 h at 180 ºC. The cooled reaction mixture was poured onto ice-water. 
The obtained precipitate was filtered, washed with ater, and dried under reduced pressure. 















The appropriate base was suspended in 40% HCl in dry MeOH, and the reaction mixture was 
vigorously stirred for 1 h at r.t. The solvent was then removed under reduced pressure, and the 
remaining solid was suspended in dry EtOH. The EtOH was removed under reduced pressure, 
and the same procedure with EtOH was repeated two more times. Upon drying at 40 ºC under 
reduced pressure, the desired product was obtained. 
General procedure for the preparation of alkylaminonaphthyridines.   
An appropriate chloronaphthyridine and the excess of appropriate amine were dissolved in 
NMP in a MW cuvette under argon. The reaction mixture was subjected to MW irradiation using 
Biotage Initiator 2.5 apparatus for 2 hours at 180 ºC. The excess of amine and NMP were 
removed under reduced pressure using Kugelrohr device. The crude product was purified by 
column chromatography (dry flash, SiO2, eluent DCM 100%, DCM/MeOH, gradient 9:1→1:9, 
MeOH 100%, MeOH/NH4OH gradient 99:1 → 8:2), unless pecified otherwise. 
In Vitro Plasma Protein Binding. 
 
Human serum albumin (HSA), alpha-1-acid glycoprotein (AGP), potassium dihydrogen 
phosphate, disodium hydrogen phosphate, sodium chloride, potassium chloride, and DMSO were 
purchased from Sigma-Aldrich. Fluorescence spectra were recorded on Horiba Jobin Yvon 
Fluoromax-4 spectrometer, equipped with Peltier elem nt and magnetic stirrer for cuvette, using 
quartz cell with 1 cm path length and 4 mL volume. UV/vis spectra were recorded on a Thermo 
Scientific Evolution 60S spectrophotometer using quartz cell with 1 cm path length and 4 mL 
volume. All UV/vis spectra were recorded against the corresponding blank in the 200−500 nm 














using Crison pH-buret 24 2S equipped with a microcombined pH electrode (Crison pH electrode 
50 29). The pH electrode was calibrated by standard Crisonbuffer solutions (pH 4.01, 7.00, and 
9.21). Stock solutions of AGP (c = 6.05×10−5 M) and HSA (c = 1.91×10−4 M) were prepared in 
PBS (1×, pH 7.34) and kept in the refrigerator. Stock solutions of compounds were prepared in 
DMSO. For protein-compound interaction studies, protein solutions were freshly prepared from 
the stock by dilution with a buffer (AGP and HSA con entration was kept constant, c=5×10-7 M) 
and titrated with compound stock solution (from 1 to 20 compound/protein molar ratio). During 
the titration, the solutions were stirred and thermostated (t=25.0±0.1°C, regulated by Peltier 
element). The equilibration time between increment additions was 10 min. An excitation 
wavelength was 280 nm, with 5 nm slits; emission spectra were recorded in 300−450 nm 
wavelength range, with 5 nm slits and 0.1 s integration time. Background PBS signal was 
subtracted from each spectrum. Fluorescence intensiti s were corrected for inner filter effect by 
measuring absorbances at excitation and emission wavelength. 
 
Cells and Cell culture 
HeLa cells (ATCC) and Human Foreskin fibroblasts (HFF) cells (ATCC) were maintained at 37 
oC in a 5% CO2 in Minimum Essential Medium (MEM) (Corning Cellgro) supplemented with 
10% fetal bovine serum (FBS, Hyclone). 
 
Viruses 
EBOV/ H. sapiens-wt/1995/Kikwit-9510621 (reference genome GenBank # KT582109; 














(USAMRIID) were used for infection and were conducted under biosafety level 4 (BSL-4) 
conditions at USAMRIID. 
 
High Content Image Based Quantification of EBOV infection and Other Phenotypes 
Cells infected with EBOV were fixed in 10% formalin (Val Tech Diagnostics) for 24 h at room 
temperature. Cells were then immunofluorescently stained to visualize EBOV-GP expression 
using murine monoclonal antibody against EBOV (6D8), followed by Dylight488-conjugated 
goat anti-mouse IgG (ThermoFisher Scientific) in blocking buffer containing 3% bovine serum 
albumin (Sigma) in phosphate buffered salt solution (PBS). DRAQ5 (Biostatus) was used to 
stain nuclei (for dose response curve analysis [DRA]). In some cases, infected cells were also 
stained with Hoechst 33342 and HCS CellMask Red (ThermoFisher Scientific) for nuclei and 
cytoplasm detection, respectively. Images were acquired on the Opera imaging instrument 
(model 3842 and 5025; PerkinElmer) using ×10 air (fo DRA), ×20 water, or ×40 water objective 
lenses as required. 4-20 images per well were acquired as described for each experiment. The 
total number of cells (based on nuclear staining) ad the number of infected cells (based on GP 
positive cells) were determined using the Acapella (Perkin Elmer) image analysis software. In 
some cases, for higher resolution, images were acquired on Leica TCS-SP5 
confocal/multiphoton microscope.  
 














The compound’s activity against EBOV including EC50 or EC90, which is the effective 
concentration to achieve 50% or 90% infection inhibition respectively, and CC50 (50% 
cytotoxicity) was accomplished by running the dose response curve analysis. Briefly, the 
compounds were tested in a 10-point dose-response curv assay at 2-fold serial dilution starting 
from 10 µM in 4 replicates (n-4) on the same plate. Table 1 represents data from one of the two 
experimental repeats performed on two consecutive days. Briefly, HeLa cells were seeded at 
2000 cells per well in 35 µL of culture media into imagin  384-well assay plates (IQ-EB, 
Aurora) using the automated MultidropTM Combi dispenser (cat # 5840300, ThermoFisher 
Sceintific). After an overnight incubation at 37 °C, cells were pre-treated at 2 h with the 
compounds using automated HP-D300 with each dose disp nsed directly from the concentrated 
stocks (10 mM). Cells were then infected with EBOV (MOI=0.5) for 48 h followed by IFA to 
detect EBOV-GP expressing cells. Images were acquired (4 images/well) and subjected to image 
analysis as described in the above sections to enumrate the number of cells and infected cells. 
Data was further evaluated by GeneData Explorer software as follows.  The percentage (%) of 
virus positive cells associated with each well was converted into percentage inhibition using 
median data from control wells as follows. 
 
NC = Neutral control (16 wells/ plate); Infection + DMSO (mock vehicle treatment) 
BC = Blank control (16 wells/plate); No infection (false positives due to background noise 


















Similarly, % Cell Viability was calculated using the following equation, that calculates the 
number of cells in a well relative to the number of cells in infected wells that were mock treated 





The % Inhibition and the % Cell Viability was then used to determine the EC50, EC90 and CC50 
values by applying the GeneData Condoseo software with LevenbergMarquardt algorithm 
(LMA) for curve fitting strategy. The Curve-fitting applied validity criteria, such aschi2, SE 
logEC50, minimal number of valid data points, to indicate if curve fitting converging was 
successful as indicated in Table 1. R2 value quantifies goodness of fit. Fitting strategy was 
considered acceptable if R2 >0.8.  The relative effctiveness of the compound is defined in terms 
of its selectivity index (SI), a value that indicates the relationship between the compound's 
effective and toxic concentrations, and is calculated as: SI = CC50/EC50. It is therefore desirable 
for a compound to have a high SI value, indicating maximum antiviral activity and minimal cell 
toxicity 
 
In Vivo Efficacy Studies against EBOV Infection 
To test the in vivo efficacy of the compounds against EBOV, mice (BALB/c; n =10/group) 
about 6-7 weeks old, were mock treated (vehicle control) or with the indicated concentrations of 
the compounds 2, 4 or 13 via the intraperitoneal (IP) route and after 2 h were infected via the IP 
route with 1000 plaque forming units (PFU) of the mouse adapted strain of EBOV (Mayinga 














All the tested compounds have a solubility of ≥25 mg/mL in deionized water. The Kaplan–
Meier survival curves are generated by GraphPad Prism software. P values were evaluated by 
comparing survival curves of individual doses with the control group using the log-rank test.  
All mouse research were conducted under an IACUC-approved protocol in compliance with 
the Animal Welfare Act, PHS Policy, and other Federal statutes and regulations relating to 
animals and experiments involving animals. The facility where this research was conducted is 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, 
International and adheres to principles stated in the Guide for the Care and Use of Laboratory 
Animals, National Research Council, 2011. 
Time of Compound Addition Assay (TCA) 
HeLa cells were seeded at 2×104 cells per well in a 96-well plate. Next day cells were either 
mock-infected or treated with compound 2 h prior to infection (pre), concurrent with virus 
infection (0 h), or at various time points post-infection as indicated in the experiment. Cells were 
infected with EBOV MOI=10. After 24 h, cells were subjected to IFA followed by HCA to 
determine the percentage of EBOV-GP expressing cells. Experiments were performed in 
triplicate and the average (± standard deviation) of tw  independent experiments is shown. 
 
Viral Entry Assay with Pseudotyped Virus 
Infectious recombinant vesicular stomatitis virus (rVSV) expressing the green fluorescent 
protein (GFP, [rVSV-GFP]) was a kind gift from Dr. John Connor [Boston University]) and 














Mayinga isolate) was a kind gift from Dr. Kartik Chandran.[58] The virus was propagated in 
Vero E6 cells and the infections were performed under BSL-2 conditions. Briefly, cells were 
infected with viruses at MOI=0.1 and the supernatants were collected at day 3-4 when >50% of 
cells became cytopathic. The virus containing supernatants were clarified and stored at -80 oC. 
To titer the virus, different volumes of virus supernatants were used to infect HeLa cells in a 96 
well plate, starting from 100 µL and serially diluted 20 times at 2/3-fold dilutions to determine 
the optimal volume of virus required to achieve 60-70% infection rates. We also determined the 
time take taken to observe the initial GFP expression even before the virus completes one life 
cycle using live cell imaging (images recorded every 15 minutes) on Opera. A time period of 8 h 
and 6 h with rVSV-EBOV-GP and rVSV-GFP respectively was determined to be optimal for 
capturing all cells expressing GFP within the first cycle of infection. The infections were scored 
by determining the percentage of GFP expressing cells using HCA. Cells and nuclei were stained 
with Cell MaskDeep Red. To determine the compounds effect on EBOV entry, HeLa cells in 96 
well plates were pre-treated at 2 h with DMSO (vehicle control) or the indicated concentrations 
of various compounds prior to incubation with rVSV-GFP (10 µL) or rVSV-EBOV-GP-GFP (50 
µl) viruses in triplicates and the infections were stopped by formalin treatment at 6 h and 8 h post 
infection respectively. This duration of infection was just enough to ensure early stages of viral 
infection including viral entry and replication (as indicated by GFP expression) but not virus 

















Visualizing Acidic Compartments and Compounds 
Acidic compartments were monitored by live cell imaging using LysoSensor DND 189 
(ThermoFisher Scientific) or Acridine Orange ([AO], ImmunoChemistry). Cells were mock 
treated or pre-treated with the compounds at the tim s indicated in the experiment. Cells were 
then incubated with the LysoSensor probe or AO at 0.5 µM and incubated at 37 oC for 30 min. 
Cells were washed, replaced with fresh media and imaged by confocal microscopy. LysoSensor 
was detected at an excitation of (Ex.443 nm) and emission of (Em.505 nm).  Monomeric AO 
(bound to nucleic acids) in green channels was visualized by Ex. 460-490 nm and Em. 520-560 
nm while the dimerized and oligomerized AO in red channel (acidic compartments) were 
visualized with Ex. 520-560 nm and Em. 590-640 nm. The compounds 1 and 2 were florescent 
and after scanning for optimal absorbance and excitation, they were imaged at Ex/Em of 405/450 
nm. At this emission, there was minimal or no bleed through by other reporters used in the study.  
 
Cathepsin B Activity 
Magic Red Cathepsin-B Assay (ImmunoChemistry) was used for detecting cathepsin activity 
by live cell imaging.  The Magic Red substrate freely diffuses into cells and emits red 
fluorescence upon cleavage by active cathepsin B. The experiment was done as following the 
manufacturer’s protocol. Briefly, cells were pre-trated with vehicle control (mock) or the 
compounds for a specific duration of time as indicated in the experiment. Cathepsin B substrate 
was then added to cells at a final dilution of 1:260 fold. Cells were incubated for 1 h at 37 oC 















As indicated for each experiment, P values were evaluated by One Way Anova analysis, ir 
multiple t tests. ***, P < 0.001. **, P < 0.01.  
 
Autophagy Detection 
HeLa-GFP-LC3 stable cell line was generated by retroviral transduction using pBABE-GFP-
LC3 (gift from Jayanta Debnath [Addgene plasmid # 22405]).[81] Cells were selected on 
Puromycin ([2 µg/mL], Sigma) for seven days. Cells were then sorted to select only medium to 
low LC3-GFP expressing cells and then analyzed for reporter activity. These cells were used for 
all experiments described. For imaging GFP-LC3 clusters, cells were seeded in 96 well plates, 
and the following day, cells were treated with compunds in 8 replicates at the concentrations 
described in the experiments for 6 h. Cells were then washed and imaged on Operetta at 20 X 
water objective at several Z planes to capture GFP clusters. Images from 20 fields per well and 
about 300 cells per well were acquired. The merged images were then analyzed for GFP clusters 
using Columbus software. Details of the script will be provided upon request and are similar to 
our previously described analysis.[82] 
For western blot analysis, HeLa-GFP-LC3 cells were counted and seeded at same numbers in 
12 well dishes. The following day, cells were treated with the indicated compounds for 6 h 
followed by cell lysis in 100 ml of 1.25X Laemmli sample loading buffer (ThermoScientific) and 
boiled for 5 min at 95 °C. Proteins were separated by SDS-PAGE, followed by transfer to a 














with the indicated primary antibodies. After three washes, the blots were incubated with the 
appropriate alkaline phosphatase (AP)-conjugated secondary antibodies (GE Healthcare) 
according to the manufacturer's recommendations. The blots were washed and developed by a 
Western blotting detection system (GE Healthcare). The following antibodies were used for 
Western blot analysis: LC3 (Abcam), GFP (BD Transduction), GAPDH (Cell Signaling), and 
alkaline phosphatase (AP) conjugated secondary antibodies (ThermoScientific).  
 
Electron Microscopy 
HeLa cells grown on a 6 well dish were treated with the compounds for 2 h followed by 
infection with rVSV-EBOV-GP-GFP (MOI = 100) at the indicated duration of time. Cells were 
fixed for 1 h in primary fixative (2.5% formaldehyde, 2.5% glutaraldehyde, 0.1 M sodium 
cacodylate, pH 7.4) and scraped off the plates to collect cell pellets.  Cells were then washed 
three times in ice-cold 0.1 M sodium cacodylate buffer, and incubated with 1% osmium tetroxide 
in 0.1 M of sodium cacodylate for 1 h, washed three tim s with distilled water, stained and 
stabilized on ice with 2% uranyl acetate for 1 h and successively dehydrated on ice through a 
series of 22%, 50%, 75%, and 95% ethanol. The cellsw re then dehydrated three times at room 
temperature in 100% ethanol and infiltrated in well-mixed 50% ethanol and 50% Durcupan 
ACM resin (Fluka, Sigma-Aldrich) for 1 h with agitation. Cells were infiltrated twice by 100% 
Durcupan ACM for 3 h with agitation, after which the samples were placed in an oven and 
polymerized at 60 °C for at least 48 h. Thin sections (approximately 80 nm) were collected and 
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AO – acridine orange; AQ – amodiaquine; CAD – cationic amphiphilic drug; CQ – 
chloroquine; CYP – Cytochrome P450; EBOV – Ebola virus; EM – electron microscopy; Em – 
emission; EVD – Ebola virus disease; Ex – excitation; GFP – green fluorescent protein; GP – 
glycoprotein; HCS – high-content screening; HeLa – cervical cancer immortal cell line from a 
30-year-old female patient named Henrietta Lacks; HFF – human foreskin fibroblasts; HOPS – 
homotypic fusion and protein sorting; hpf – hours po t fertilization; LC3 – Microtubule-
associated proteins 1A/1B light chain 3B; LE – late endosome; MDCK – Madin-Darby Canine 
Kidney cells, a kidney tubule cell line from a Cocker Spaniel dog; MOA – mechanism of action; 
MOI – multiplicity of infection; HNP – non-human primates; NPC1 – Niemann-Pick disease 
type C1 (protein); PFU – plaque forming units; Pgp – P-glycoprotein; RNP – ribonucleoprotein 
complex; (r)VSV – (recombinant) vesicular stomatitis v rus; SNARE – soluble NSF (N-
ethylmaleimide-sensitive factor) attachment protein r ceptor; TCA – time of compound addition  
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1. Second generation diazachrysene protects mice from Ebola virus 
2. Naphthyridines are a new class of compounds active against Ebola virus 
3. Favorable pharmacokinetics, tolerability and efficacy in in vivo mouse models  
4. Mechanism of action tied to acidic compartment; host based; shows unique features 
5. Diazachrysene enhances vesicle expansion and enables virus internalization 
